Literature DB >> 25435590

Improvements in the Synthesis and Understanding of the Iodo-bridged Intermediate en Route to the Pt(IV) Prodrug Satraplatin.

Timothy C Johnstone1, Stephen J Lippard1.   

Abstract

Mixed amine/ammine motifs are important features in newer generation platinum anticancer agents, including the Pt(IV) prodrug satraplatin. One synthetic route that can be used to access platinum molecules with such structures exploits the trans effect during NH3-mediated cleavage of iodo-bridged platinum(II) dimers of the form [Pt(Am)I(μ-I)]2, where Am is an amine. A clear picture of the nature of these dimers that is consistent with the reactivity they exhibit has remained elusive. Moreover, technical aspects of this chemistry have impeded its more widespread use. We present here an improved strategy that permits isolation and use of [Pt(Am)I(μ-I)]2, where Am is cyclohexylamine, within minutes as opposed to weeks, as previously reported. A detailed spectroscopic, crystallographic, and chromatographic investigation of this intermediate in the synthesis of satraplatin is also presented with a discussion of the ability of both cis and trans isomers of the dimer to produce exclusively cis-[Pt(NH2C6H11)(NH3)I2] upon treatment with NH3.

Entities:  

Keywords:  cisplatin; iodo-bridged dimer; multinuclear NMR; platinum anticancer agents; satraplatin

Year:  2015        PMID: 25435590      PMCID: PMC4243179          DOI: 10.1016/j.ica.2014.08.047

Source DB:  PubMed          Journal:  Inorganica Chim Acta        ISSN: 0020-1693            Impact factor:   2.545


  16 in total

1.  Space group Cc: an update.

Authors:  Richard E Marsh
Journal:  Acta Crystallogr B       Date:  2004-03-18

2.  Carboxylation of Kinetically Inert Platinum(IV) Hydroxy Complexes. An Entr.acte.ee into Orally Active Platinum(IV) Antitumor Agents.

Authors:  C M Giandomenico; M J Abrams; B A Murrer; J F Vollano; M I Rheinheimer; S B Wyer; G E Bossard; J D Higgins
Journal:  Inorg Chem       Date:  1995-03       Impact factor: 5.165

3.  Synthesis, characterization, and anticancer activities of the first platinum complexes from sucrose.

Authors:  N D Sachinvala; H Chen; W P Niemczura; E Furusawa; R E Cramer; J J Rupp; I Ganjian
Journal:  J Med Chem       Date:  1993-06-11       Impact factor: 7.446

4.  Synthesis and antitumor activity of ammine/amine platinum(II) and (IV) complexes.

Authors:  A R Khokhar; Y Deng; S al-Baker; M Yoshida; Z H Siddik
Journal:  J Inorg Biochem       Date:  1993-08-15       Impact factor: 4.155

5.  Synthesis, physical properties, and antitumor activity of tetraplatin and related tetrachloroplatinum(IV) stereoisomers of 1,2-diaminocyclohexane.

Authors:  W K Anderson; D A Quagliato; R D Haugwitz; V L Narayanan; M K Wolpert-DeFilippes
Journal:  Cancer Treat Rep       Date:  1986-08

6.  Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines.

Authors:  Frantisek Zák; Jaroslav Turánek; Ales Kroutil; Petr Sova; Adolf Mistr; Anna Poulová; Petr Mikolin; Zdirad Zák; Andrea Kasná; Dana Záluská; Jirí Neca; Lenka Sindlerová; Alois Kozubík
Journal:  J Med Chem       Date:  2004-01-29       Impact factor: 7.446

7.  Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.

Authors:  L R Kelland; G Abel; M J McKeage; M Jones; P M Goddard; M Valenti; B A Murrer; K R Harrap
Journal:  Cancer Res       Date:  1993-06-01       Impact factor: 12.701

8.  Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines.

Authors:  L R Kelland; B A Murrer; G Abel; C M Giandomenico; P Mistry; K R Harrap
Journal:  Cancer Res       Date:  1992-02-15       Impact factor: 12.701

9.  Monofunctional and higher-valent platinum anticancer agents.

Authors:  Timothy C Johnstone; Justin J Wilson; Stephen J Lippard
Journal:  Inorg Chem       Date:  2013-06-05       Impact factor: 5.165

10.  Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.

Authors:  Cora N Sternberg; Daniel P Petrylak; Oliver Sartor; J Alfred Witjes; Tomasz Demkow; Jean-Marc Ferrero; Jean-Christophe Eymard; Silvia Falcon; Fabio Calabrò; Nicholas James; Istvan Bodrogi; Peter Harper; Manfred Wirth; William Berry; Michael E Petrone; Thomas J McKearn; Mojtaba Noursalehi; Martine George; Marcel Rozencweig
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.